Cases & Deals

Baxter Ventures invests in TVA Medical

Clients Baxter International Inc.

Jones Day represented Baxter Ventures in connection with its purchase of Series C Preferred Stock in a private placement by TVA Medical, Inc., a developer of minimally invasive therapies for end-stage renal disease. The round was led by newly vested Baxter Ventures and joined by new investor Boston Scientific and returning investors Sante Ventures, S3 Ventures, and TriStar Technology Ventures.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.